NGEN — NERVGEN PHARMA CORP.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1751912 · British Columbia, Canada
Last close
$1.96
Market Cap
$210.74M
52W High
$6.30
52W Low
$1.28
ADV30
631,669
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -12,196,618 -29,217,233 90,190,914 86,789,698 72,913,623
Mar 2026 0 — -7,531,578 -1,675,549 20,765,547 16,559,056 15,223,975
Dec 2025 0 — -6,404,283 -26,908,856 23,209,641 22,069,635 19,732,715
Sep 2025 0 — -6,170,687 -4,156,070 13,077,452 11,364,055 16,019,155

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,647,717
Investing CF
$58,874
Financing CF
$98,663,069
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-177,656,300
Inventory
—
Receivables
$200,236
ST Investments
$0
EBIT TTM
$-30,177,102
Pretax Income TTM
$-22,034,686
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -25,079,252 -44,117,305 23,209,641 19,732,715 3,476,926 -19,499,211
Dec 2024 0 -25,176,149 -24,250,049 19,486,223 16,909,616 2,576,607 -16,841,034
Dec 2023 0 -17,776,710 -22,382,120 13,236,021 15,245,126 -2,009,105 -11,295,594
Dec 2022 0 -23,025,033 -20,722,283 23,875,217 10,414,137 13,461,080 -17,784,163
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34

Max Pain — expiry 2027-03-19

max pain strike: $2.50 · spot: $1.90 · call oi: 1,031 · put oi: 0
Expected Move to 2027-03-19: ±$1.03 (54.47%) — implied range $0.86 – $2.93 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ACIU AC Immune SA $209.79M $2.11 —
LAB STANDARD BIOTOOLS INC. $212.95M $0.54 —
PRLD Prelude Therapeutics Inc $216.05M $3.32 —
CYPH CYPHERPUNK TECHNOLOGIES INC. $205.29M $1.90 —
DRUG BRIGHT MINDS BIOSCIENCES INC. $201.25M $20.51 —

News headlines (Yahoo Finance, 1h cache)

NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
2026-11-18 12:15 · Yahoo
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-16 12:15 · Yahoo
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
2026-11-12 12:15 · Yahoo
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
2026-10-12 11:15 · Yahoo
NervGen to Host Inaugural R&D Day on September 30, 2026
2026-09-09 11:30 · Yahoo
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 11:30 · Yahoo
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
2026-05-26 11:15 · Yahoo
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
2026-05-22 03:27 · Yahoo
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-18 11:15 · Yahoo
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
2026-09-25 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.